Skip to main content

Advertisement

Table 5 Literature review

From: Secretory carcinoma: the eastern Canadian experience and literature review

Study Number of Patients Tumor Location n (%) Treatment n (%) Initial Nodal Diseaseb, n (%) Survival % (cause; timing) Recurrence n (%); timing Regional metastasis n (%); timing Distant metastasis n (%); location timing
Aizawa et al. 2016 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 1 (100); 2 years 0 (0)
Baghai et al. 2017 10 Parotid: 9 (90) MSG: 1 (10) Surgery: 10 (100) LND: 3 (30) ART: 4 (40) ACRT: 1 (10) 3 (30) 66% (DOD; 24 months, 18 months) 3 (30); 3, 5, 120 months 0 1 (10); bone 15 months
Balanza et al. 2015 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Boon et al. 2018 31 Parotid: 18 (58) SMG: 1 (3) MSG: 12 (39) Surgery: 31 (100) LND: 4 (13) ART: 15 (48) 1 (3) 97% (DOC; 48 months) 1 (3); 50 months 0 (0) 0 (0)
Chiosea et al. 2012 36 Parotid: 26 (72) SMG: 3 (10) MSG: 7 (24) Surgery: 36 (100)LND: 18 (50)ART: 5 (14)ACRT: 2 (6) 4 (11) 97% (DOD; time unknown) 3 (8); time unknown 0 (0) 1 (3); unknown
Cipriani et al. 2017 1 MSG: 1 (100) Surgery: 1 (100) 0 (0) 0% (DOD; 3 months) 0 (0) 0 (0) 1 (100); lungs 2 months
Cooper et al. 2013 2 MSG: 2 (100) Surgery: 2 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Din et al. 2016 11 Parotid: 7 (64)SMG: 3 (27)MSG: 1 (9) Surgery: 10 (91)ART: 2 (18)ACRT: 2 (18) 2 (18) 91% (DOD; 5 years) 3 (38)a; time unknown 0 (0) 0 (0)
Drilon et al. 2016 1 Parotid: 1 (100) Surgery: 1 (100)ART: 1 (100)Revision Surgery: 3 procedureCrizotinibEntrectinib 0 (0) 100% 0 (0) 0 (0) 1 (100); lungs 5.5 years
Fakhoury et al. 2016 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Griffith et al. 2013 6 Parotid: 4 (67)SMG: 1 (17)MSG: 1 (17) Surgery: 5 (83)LND: 3 (50)No treatment: 1 (17) 1 (17) 100% 0 (0) 0 (0) 0 (0)
Helkamaa et al. 2015 1 MSG: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Higuchi et al. 2014 7 Parotid: 6 (86)SMG: 1 (14) Surgery: 7 (100)ART: 1 (14) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Hijazi et al. 2014 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Hwang et al. 2014 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Inaba et al. 2015 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Ito et al. 2015 14 Parotid: 9 (64)SMG: 1 (7)MSG: 4 (29) Surgery: 14 (100) 2 (14) 100% 1 (20)a; 90 months   0 (0)
Jackson et al. 2017 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Jung et al. 2013 13 Parotid: 11 (85)Unknown: 2 (15) Surgery: 13 (100)ART: 2 (15) 0 (0) 100% 3 (23); 10–101 months (mean 44) 0 (0) 0 (0)
Jung et al. 2015 9 Parotid: 9 (100) Unknown Unknown Unknown 3 (33); time unknown 0 (0) 0 (0)
Kratochvil et al. 2012 2 MSG: 2 (100) Surgery: 2 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Laco et al. 2013 2 Parotid: 1 (50)SMG: 1 (50) Surgery: 2 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Levine et al. 2014 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Luk et al. 2015 9 Parotid: 9 (100) Surgery: 9 (100)LND: 1 (11)ART: 1 (11) 1 (11) 89% (DOD; 13 months) 0 (0) 1 (11); 12 months 0 (0)
Luo et al. 2014 1 MSG: 1 (100) Surgery: 1 (100)ART: 1 (100) 1 (100) 100% 0 (0) 0 (0) 0 (0)
Majewska et al. 2015 7 Parotid: 6 (86)MSG: 1 (14) Surgery: 7 (100)LND: 2 (29)ART: 2 (29) 3 (43) 71% (DOD; 20 months, 79 months) 2 (29); 4 months, 10 months 1 (14); 48 months 0 (0)
Mossinelli et al. 2018 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Ngouajio et al. 2017 1 Parotid: 1 (100) Surgery: 1 (100)LND: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Oza et al. 2016 3 Parotid: 3 (100) Surgery: 3 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Rastatter et al. 2012 1 Parotid: 1 (100) Surgery: 1 (100)LND: 1 (100) 1 (100) 100% 0 (0) 0 (0) 0 (0)
Salat et al. 2015 2 Parotid: 2 (100) Surgery: 2 (100)LND: 1 (50)ART: 2 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Serrano-Arevalo et al. 2015 4 Parotid: 1 (25)SMG: 1 (25)MSG: 2 (50) Surgery: 2 (50)Nothing: 2 (50)ART: 1 (25) 1(25) 100% 0 (0) 0 (0) 0 (0)
Shah et al. 2015 1 Parotid: 1 (100) Surgery: 1 (100) 0 (0) 100% 0 (0) 0 (0) 0 (0)
Skalova et al. 2010 16 Parotid: 13 (81)MSG: 3 (19) Surgery: 16 (100)ART: 7 (44)LND: 1 (6) 1 (6) 94% (DOD; 6 years) 3 (19), 6 months, 2 years, 6 years 1 (6); 86 months 1 (6); lungs 2 years
Skalova et al. 2014 3 Parotid: 3 (100) Surgery: 3 (100)ART: 2 (67)LND: 1 (33) 0 (0) 0% (3 DOD; 20 months, 4 years, 6 years) 2 (66); 2 years, 6 years 2 (67); 20 months, 4 years 2 (67); dissemintated 20 months, 4 years
Skalova et al. 2018 10 Parotid: 7 (70)SMG: 2 (20)MSG: 1 (10) Surgery: 9 (90)LND: 1 (10)ART: 1 (10)ACRT: 1 (10)Nothing: 1 (10) 1 (10) 78% (1 DOD; 2 years. 1 DOC; 3 years)a 0 (0) 1 (11); time unknown 1 (11); bone 15 months
Stevens et al. 2015 14 Parotid: 9 (64)Thyroid: 1 (7)SMG: 1 (7)MSG: 3 (21) Surgery: 12 (88)Nothing: 2 (14)ART: 3 (21) 2 (14) 100% 1 (7); 4 years 0 (0) 1 (7);lungs 4 years
Total 227 Parotid: 166 (73)Other: 61 (27) Surgery: 211 (97)cLND: 37 (17)ART: 56 (26) 24 (11) 93% (13 DOD, 2 DOC)cMean time: 38 monthsd 26 (12) 8 (4) 9 (4)Mean time: 30 monthsc, d
  1. ART adjuvant radiotherapy, ACRT adjuvant chemoradiotherapy, LND lymph node dissection, MSG minor salivary gland, SMG submandibular gland, DOD died of disease, DOC died of other causes
  2. astudy includes patients lost to follow up, b: category includes patients with clinically evident nodes, or those that had lymph node dissection, c: Jung et al. 2014 not included, d: Mean time dos not include Chiosea et al